curcuminNatural turmeric


Synthetic Curcumin – LipoCurc

Curcumin-like compounds are found in a genus of root vegetables that includes turmeric and ginger; they have been consumed for thousands of years and epidemiological evidence suggests real health benefits.
Curcumin in its natural form is very poorly absorbed so only limited amounts get into the body.  Signpath’s proprietary liposomal formulation achieves high bioavailability.
SignPath uses only synthetic curcumin for its proprietary formulation.  The drug (LipoCurcTM) is injected directly into the blood to achieve pharmacologically effective concentrations.
In low doses, curcumin is anti-inflammatory; it reduces the production of cytokines including Interleukins (IL), Tumor Necrosis Factor (TNF) and Interferon, among others.
In high doses curcumin promotes cell death (apoptosis) especially in tumors.

Cancer Indications Currently In Clinical Development

Phase 1a human clinical trial of LipoCurcTM in 50 normal subjects is complete.  The only adverse effect noted was grade 1 echinocytosis ( reversible alteration of red blood cell membranes)

In the 4th quarter of 2016, phase 1b dose escalation trials were completed in  salvage patients with solid tumor cancers in  Salzburg Austria.  This clinical trial confirmed previous data regarding toxicity of LipoCurcTM and  has shown that the drug is well tolerated with no limiting adverse effects.

Using the data generated from the Phase 1 trials, we are preparing for a Phase 2 trial in glioblastoma patients who have failed first line therapy.  We expect to initiate this Phase 2 trial in 2017.


.resultsmicePicture. In vivo efficacy study of four nude mice bearing xenografts of human pancreatic cancer metastatic cancer cell line Pa03C. Tumor sizes in mice treated parenterally with polymer alone, nanocurc®, gemcitabine or nanocurcumin+gemcitabine revealed no discernable tumor at the end of week #3 in the combination-treated mouse (Courtesy of Dr A. Maitra, Johns Hopkins University School of Medicine)


curcgraphGraph:  NCI-H460 lung cancer cells exhibit dose dependent changes in cell morphology, viability, cell cycle, mRNA and protein expressions when treated with curcumin. The cells tend to be arrested at the G2/M cell cycle stage after curcumin treatment and down-regulation of cyclin-dependent kinase.


Mechanism of Action

The mechanism of action  of liposomal curcumin and lung cancer is in part due to curcumin  activation of sphingomyelinase  leading to an increased ceramide/S1P ratio. The increased ceramide activates growth inhibition and  cell death mechanisms.